AOU Città della Salute e della Scienza di Torino – PO Molinette

Protocolli di Ricerca Clinica in ambito oncologico:

Disordini linfoproliferativi AOU CDSS

Divisione Universitaria di Ematologia (Prof. Benedetto Bruno)

Divisione Ospedaliera di Ematologia (Dott. Freilone Roberto)

Titolo:	290028-2223_001* (1°T 2026) "A Phase 1, Multicenter, Open-label, Non-randomized, Dose-escalation and Backfill Study of KK2223 (Antibody Drug Coniugate anti CCR4-Calicheamicin G) in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma"
Patologia:	T-cell Non-Hodgkin Lymphoma RECIDIVA
Tipo di Studio:	INTERVENTISTICO, BRACCIO SINGOLO
Fase:	I
Principali criteri di inclusione:	• Patients with one of the following subtypes of T-cell lymphoma: PTCL (Part 1 and Part 2): Nodal T-follicular helper cell lymphoma (angioimmunoblastic-type, follicular-type,), ALCL (ALK-positive or negative), PTCL not otherwise specified; CTCL (Part 1 only): Mycosis fungoides and Sézary syndrome whose stages are IIB to IV; CTCL (Part 2 only): Mycosis fungoides and Sézary syndrome whose stages are 1 cm in diameter) or lymphnode or visceral involvement (M1) or LCT. • Participants with PTCL who have relapsed from or are refractory to or are intolerant to at least one prior systemic therapy; participants with known CD30+ PTCL (ALCL for EU sites) must have previously been treated with or be intolerant to brentuximab vedotin, and/or participants with ALK-positive ALCL should have previously received crizotinib if indicated. Participants with CTCL who have relapsed from or are refractory to or are intolerant to at least two prior systemic therapies. Participants with PTCL must have at least one measurable (LDi > 1.5 cm for nodal or LDi > 1.0 cm for extranodal) lesion . Participants with CTCL must have assessable skin

Principali criteri di esclusione:	
Sede e contatti	TORINO, MOLINETTE Divisione Universitaria di Ematologia PI: Prof.ssa Federica Cavallo (f.cavallo@unito.it) Study Coordinator: Irene Scavini (irene.scavini@unito.it)